293 related articles for article (PubMed ID: 28063135)
1. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
Ericsson Å; Lundqvist A
Appl Health Econ Health Policy; 2017 Apr; 15(2):237-248. PubMed ID: 28063135
[TBL] [Abstract][Full Text] [Related]
2. Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.
Davies MJ; Glah D; Chubb B; Konidaris G; McEwan P
Pharmacoeconomics; 2016 Sep; 34(9):953-66. PubMed ID: 27438706
[TBL] [Abstract][Full Text] [Related]
3. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
Dempsey M; Mocarski M; Langer J; Hunt B
Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
[TBL] [Abstract][Full Text] [Related]
4. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
Drummond R; Malkin S; Du Preez M; Lee XY; Hunt B
Diabetes Obes Metab; 2018 Oct; 20(10):2371-2378. PubMed ID: 29797389
[TBL] [Abstract][Full Text] [Related]
5. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
Dempsey M; Mocarski M; Langer J; Hunt B
J Med Econ; 2018 Nov; 21(11):1110-1118. PubMed ID: 30114954
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
Hunt B; Mocarski M; Valentine WJ; Langer J
J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
Raya PM; Blasco FJA; Hunt B; Martin V; Thorsted BL; Basse A; Price H
Diabetes Obes Metab; 2019 Jun; 21(6):1349-1356. PubMed ID: 30740861
[TBL] [Abstract][Full Text] [Related]
9. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
Hunt B; Mocarski M; Valentine WJ; Langer J
Adv Ther; 2017 Apr; 34(4):954-965. PubMed ID: 28281218
[TBL] [Abstract][Full Text] [Related]
11. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
Aroda VR; González-Galvez G; Grøn R; Halladin N; Haluzík M; Jermendy G; Kok A; Őrsy P; Sabbah M; Sesti G; Silver R
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):596-605. PubMed ID: 31189519
[TBL] [Abstract][Full Text] [Related]
12. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
Jendle J; Ericsson Å; Ekman B; Sjöberg S; Gundgaard J; da Rocha Fernandes J; Mårdby AC; Hunt B; Malkin SJP; Thunander M
J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
[TBL] [Abstract][Full Text] [Related]
13. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
15. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
Watada H; Kaneko S; Komatsu M; Agner BR; Nishida T; Ranthe M; Nakamura J
Diabetes Obes Metab; 2019 Dec; 21(12):2694-2703. PubMed ID: 31423685
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.
Ericsson Å; Glah D; Lorenzi M; Jansen JP; Fridhammar A
PLoS One; 2018; 13(2):e0191953. PubMed ID: 29408938
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
[TBL] [Abstract][Full Text] [Related]
18. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
Vilsbøll T; Vora J; Jarlov H; Kvist K; Blonde L
Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
[TBL] [Abstract][Full Text] [Related]
19. Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
Vilsbøll T; Blevins TC; Jodar E; Poulter N; Tentolouris N; Ross Agner BF; Lehmann L; Leiter LA
Diabetes Obes Metab; 2019 Jun; 21(6):1506-1512. PubMed ID: 30785655
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
